GPC3 and hepatocellular carcinoma: In 2020, Shi et al. [160] reported two sequential phase I studies, NCT02395250 and NCT03146234, which showed that GPC3-CAR-T cells have an initial safety profile and anti-tumor activity in advanced HCC patients.